Tailai Biosciences Completes Tens of Millions RMB Pre-A Financing to Accelerate Multi-Omics Liquid Biopsy Development

VCBeat has learned that TaiLai Biosciences, a biotechnology company focused on the development of next-generation liquid biopsy technologies and products based on multi-omics, has announced the completion of its Pre-A financing round amounting to tens of millions of RMB. The round was jointly invested by prominent healthcare institutions including Ruifu Healthcare Fund, KingMed Diagnostics (Kangsheng Global), and Kunpeng Medical Angel Fund, with Huanghe Capital serving as the exclusive financial advisor for this round. It is understood that the funds will be primarily used to support the construction and layout of the company’s third-party medical laboratory, apply for professional qualifications for pan-cancer screening products, and conduct R&D related to clinical products for specific diseases.

TaiLai Biosciences was founded in June 2018. Leveraging fully independent intellectual property rights and proprietary technologies, the company has established multiple product and technology pipelines based on various multi-omics technologies. These include high-throughput pan-cancer general screening products, precise single-disease screening technologies, and high-precision clinical diagnostic products for specific diseases. Mr. Liu Yaokun, CEO of TaiLai Biosciences, told VCBeat that the Chair of the company’s Scientific Advisory Committee is Professor Michael Snyder, Chair of the Department of Genetics at Stanford University and a leading pioneer scientist in human multi-omics technologies. The company’s joint technical R&D partner is the National Engineering Research Center for Biomaterials in China, a world-leading professional R&D institution in biomaterials that has been featured in an in-depth article in the main journal of Nature. The company’s scientific and technical team comprises researchers from multiple frontier scientific fields, including biochemistry, molecular biology, bioengineering, biomaterials engineering, and data science, possessing strong interdisciplinary comprehensive R&D capabilities for complex challenges. Guided by a professional leadership team with extensive experience in the pharmaceutical industry, the company has collected real-world multi-omics human data from over 20,000 cases, filed dozens of invention patents and software copyrights, and successfully developed various omics-based diagnostic technologies and products leveraging metabolomics and epigenomics within less than two years of its establishment.

Currently, TaiLai Biosciences has built a robust pipeline of products in development to address unmet clinical needs in health management and disease diagnosis. Its scientific achievements have been presented at multiple prestigious medical conferences, including ESMO and CSCO. The company’s continuously iterated technologies and products have gained recognition from renowned Grade A tertiary hospitals, leading health examination institutions, and a broad user base.

In the realm of health screening, TaiLai Biosciences’ independently developed pan-cancer screening product, Meta-Pan™ (An An Pan™), leverages proprietary “laser + nanomaterial” technology. By conducting high-throughput detection and analysis of a panel of 432 metabolic biomarkers, it enables highly specific and sensitive screening for a total of 14 types of malignant tumors with the highest incidence rates in China. According to Dr. Zhong Sheng, Vice President of Medical Research and Expansion at TaiLai Biosciences, the company is collaborating with multiple Grade IIIA hospitals across China on comprehensive, cross-departmental sample studies based on Meta-Pan™. The aim is to establish and refine a world-leading real-world case database. “Since the first quarter of 2019, we have accumulated over 20,000 real-world patient data records, helping us continuously optimize our algorithms and products,” said Dr. Zhong.

In addition, the third-party medical laboratories established by TaiLai Biosciences in Shanghai, Chengdu, and other locations have gradually become operational. Together with sample storage centers and collection points distributed across North, East, Central, South, and West China, they form a nationwide screening service network. This network facilitates the rapid delivery of Meta-Pan™ and subsequent early-screening products to users, enabling earlier disease detection, targeted treatment, and improved health management. For instance, in September 2019, Meta-Pan™ was invited to join the “Benevolent Doctors Benefiting the People: Love in Yangcheng” health initiative in Guangzhou, providing early cancer screening tests to nearly 1,000 elderly residents in the Guangzhou area and receiving widespread acclaim from all sectors of society.

In the realm of disease diagnosis, TaiLai Biosciences has established an in-development product pipeline covering high-incidence malignant tumors such as liver cancer, lung cancer, and gastric cancer. This initiative addresses critical clinical needs, including auxiliary disease diagnosis, medication guidance for complex diseases, and cancer recurrence monitoring. The company has formed collaborations with multiple leading hospitals, including Zhongshan Hospital Fudan University, West China Hospital Sichuan University, and the National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences, as well as with numerous leading pharmaceutical companies both domestically and internationally.

According to Dr. Zhong Sheng, the company has accumulated substantial technical expertise in the development of clinical diagnostic products over its past growth. For instance, TaiLai Biosciences, in collaboration with Zhongshan Hospital Affiliated to Fudan University and Mengchao Hepatobiliary Hospital Affiliated to Fujian Medical University, jointly developed an auxiliary diagnostic technology for liver cirrhosis-to-hepatocellular carcinoma transformation. This technology enables non-invasive, point-of-care differentiation between benign and malignant tumors smaller than 3 cm. Concurrently, a hepatocellular carcinoma recurrence monitoring technology was developed, leveraging high-throughput multi-omics data analysis to rapidly and efficiently predict whether and when patients are likely to experience recurrence. Furthermore, in partnership with internationally renowned pharmaceutical companies and the Cancer Hospital of the Chinese Academy of Medical Sciences, TaiLai Biosciences developed a PD-1 inhibitor response prediction technology that integrates comprehensive omics data, achieving accuracy in predicting patient response to PD-1 inhibitors significantly above the average level.

Dr. Zhong Sheng pointed out that, at the current stage, TaiLai Biosciences’ multiple in-development clinical diagnostic pipelines and products have reached maturity. “We have successively initiated professional qualification applications for relevant products, or are collaborating with researchers to conduct clinical studies.”

Professor Huang Shiang, CEO of KingMed Diagnostics Global, stated that in recent years, the application of multi-omics technologies in the field of liquid biopsy has become increasingly mature, with promising prospects, driven by the use of artificial intelligence algorithms in the processing and analysis of ultra-high-dimensional biological signals. TaiLai Biosciences boasts a combination of a first-class scientific team and outstanding industry leaders. We are delighted to see that some of the company’s product pipeline has gained recognition and support from experts at top-tier hospitals and the National Center for Biomedical Materials. As a group enterprise committed to leading specialized diagnostic testing technologies in China, KingMed Diagnostics Global will provide strong support in various aspects, including capital and industrial resources, to help TaiLai Biosciences make its products accessible to a broader population at an earlier stage.

Mr. Huang Ruijin, Founding Managing Partner of Ruifu Healthcare Fund, stated that existing liquid biopsy products on the market fall far short of meeting the demands of the trillion-yuan-scale markets for critical illness health screening and professional clinical in vitro diagnostics. In the consumer health sector, China’s economic growth is driving structural upgrades in health consumption, with a pressing need to significantly increase the rate of early diagnosis and treatment. There is a market gap for pan-cancer general screening products that offer high specificity, high sensitivity, and high service throughput. In the clinical market, alongside the rapid development of precision medicine, multi-omics technologies enable large-scale, multi-dimensional data observation and analysis at the molecular level. With their advantages of being non-invasive, dynamic, and highly accessible, these technologies hold promise for addressing certain challenges in scenarios such as auxiliary diagnosis, medication guidance, and recurrence monitoring. TaiLai Biosciences boasts world-class independent R&D innovation capabilities and high technological barriers. We hope to support the team in leveraging breakthrough technologies to address unmet real-world market needs and benefit the public.

Ms. Guan Qi, Managing Partner of Kunpeng Medical Angel Fund, stated that in recent years, China’s cancer incidence and mortality rates have remained persistently high, with the five-year cancer survival rate lagging significantly behind that of developed countries. For many patients, diagnosis occurs at a markedly advanced stage, causing them to miss the optimal window for treatment. This results in diminished quality of life for patients and imposes excessive economic burdens on families and society. We look forward to TaiLai Biosciences’ technological achievements serving a broader population and becoming a powerful tool for “early detection and early treatment.”

TaiLai Biosciences was co-founded by a seasoned medical industry team and a cutting-edge scientific team comprising top-tier experts, professors, Ph.D. holders, and scientists in the field. It is a biotechnology company that provides next-generation biopsy products and services based on proprietary multi-omics technologies.

Revo Healthcare Fund focuses on investing globally in early- and growth-stage companies in the life sciences and healthcare sectors that are R&D-driven, innovative, and protected by high technological barriers. The fund aims to address unmet medical needs and improve patients’ quality of life through breakthrough technologies and inventions. Its investment team comprises the former life sciences investment team from KPCB China, a globally renowned venture capital firm, along with seasoned industry experts.

Kindstar Global Medical Specialized Testing Group (hereinafter referred to as “Kindstar Global”) is a large-scale, high-end specialized medical testing group in China. It is committed to leading advancements in specialized testing technologies and services in China, thereby promoting the development and enhancement of specialized diagnosis and treatment as well as personalized medicine. Adhering to the principles of prioritizing patient interests and placing physicians’ needs first, Kindstar Global follows international norms, standards, and industry guidelines. The company introduces and develops advanced global technologies and specialized testing methodologies, providing comprehensive, cutting-edge, and accurate specialized testing services to major tertiary hospitals, specialized hospitals, and general hospitals across China. The core members of the Group’s founding and management teams have each worked for over ten years in academic and industrial sectors in the United States, bringing extensive experience and a broad global perspective.

The Kunpeng Medical Angel Fund was co-founded by a group of seasoned healthcare industry professionals, including medical sector investors, former executives from Fortune 500 pharmaceutical companies, and entrepreneurs. The team possesses extensive experience in project screening, commercial operations, and corporate management within the healthcare industry. It is dedicated to identifying and supporting emerging innovative enterprises in the medical field, jointly creating greater economic and social value.